IRVINE, Calif., Nov. 21, 2017 /PRNewswire/ -- Novus
Therapeutics, Inc. (NASDAQ: NVUS), a development stage specialty
pharmaceutical company focused on the development of products for
disorders of the ear, nose, and throat (ENT), announced today that
Gregory J. Flesher, Chief Executive
Officer, will present at the Piper Jaffray 29th Annual Healthcare
Conference on Wednesday, November 29
at 2:10 p.m. ET at the Lotte New York
Palace.
About Novus Therapeutics
Novus Therapeutics is a development stage specialty
pharmaceutical company focused on the development of products for
disorders of the ear, nose, and throat (ENT). Novus has two
technologies, each of which has the potential to be developed for
multiple ENT indications. The company's lead product (OP-02) is a
surfactant-based, combination drug product being developed as a
potential first-in-class treatment option for patients at risk for
or with otitis media ("OM") (middle ear inflammation and effusion
with or without infection). Globally, OM affects more than 700
million adults and children every year. OM is a common
disorder seen in pediatric practice, and in the United States is the most frequent reason
children are prescribed antibiotics and undergo surgery.
Novus also has a foam-based drug delivery technology (OP-01), which
may be developed in the future to deliver drugs into the ear,
nasal, and sinus cavities. For more information please visit
novustherapeutics.com.
Investor Contacts
The Trout Group
Gita Ogawa
Tel: (646) 378-2949
gogawa@troutgroup.com
Novus Therapeutics, Inc.
Investor Relations
Tel: (949) 238-8090
investors@novustherapeutics.com
View original content with
multimedia:http://www.prnewswire.com/news-releases/novus-therapeutics-to-present-at-the-29th-annual-piper-jaffray-healthcare-conference-300560458.html
SOURCE Novus Therapeutics, Inc.